1035690-24-4

Usage

Uses

Used in Organic Synthesis:
2-(3-Cyclopropoxy-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane is used as a reagent in organic synthesis for its ability to form stable boronate complexes with diols and other nucleophiles. This property is crucial in the formation of carbon-carbon and carbon-heteroatom bonds, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(3-Cyclopropoxy-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane is used as a key intermediate in the synthesis of various drugs and bioactive compounds. Its unique structure and reactivity make it a versatile building block for the development of new pharmaceutical agents.
Used in Medicinal Chemistry Research:
2-(3-Cyclopropoxy-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane is also utilized as a tool in medicinal chemistry research. Its ability to form stable boronate complexes allows researchers to explore new chemical reactions and pathways, leading to the discovery of novel bioactive compounds and potential drug candidates.
Used in the Synthesis of Complex Natural Products:
2-(3-Cydopropoxy-phenyl)-4,4,5,5-tetraMethy-[1,3,2]dioxaborolane is used as an intermediate in the synthesis of complex natural products, which often possess significant biological activities. The unique reactivity of 2-(3-Cyclopropoxy-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane enables the efficient construction of intricate molecular frameworks, facilitating the development of new natural product-inspired therapeutic agents.
Used in the Preparation of Functionalized Materials:
Due to its versatile structure, 2-(3-Cyclopropoxy-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane is employed in the preparation of various functionalized materials. Its ability to form stable boronate complexes with different nucleophiles allows for the development of materials with tailored properties, such as improved stability, reactivity, or selectivity, which can be applied in various fields, including catalysis, sensors, and advanced materials.

Upstream product

• 1035690-22-2 1-bromo-3-(cyclopropyloxy)benzene 
• 73183-34-3 bis(pinacol)diborane 
• 591-20-8 3-Bromophenol 

Downstream Products

• 1142227-99-3 (3'-(cyclopropyloxy)-2-(2,2-dimethylcyclopentyI)-1,1'-biphenyl-4-yl)methanol 
• 1142227-97-1 methyl 3'-(cyclopropyloxy)-2-(2,2-dimethylcyclopentyI)-1,1'-biphenyl-4-carboxylate 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway

Reported is the identification of the furo[3,2-b]pyridine core as a novel scaffold for potent and highly selective inhibitors of cdc-like kinases (CLKs) and efficient modulators of the Hedgehog signaling pathway. Initially, a diverse target compound set was prepared by synthetic sequences based on chemoselective metal-mediated couplings, including assembly of the furo[3,2-b]pyridine scaffold by copper-mediated oxidative cyclization. Optimization of the subseries containing 3,5-disubstituted furo[3,2-b]pyridines afforded potent, cell-active, and highly selective inhibitors of CLKs. Profiling of the kinase-inactive subset of 3,5,7-trisubstituted furo[3,2-b]pyridines revealed sub-micromolar modulators of the Hedgehog pathway.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS

A compound of formula (I) wherein : - one of the groups G1represents a nitrogen atom or a group CRc and the other represents a group CRc; - G2 represents a nitrogen atom or a group CRd; - R1 represents a group selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - R2 represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - Ra, Rb and Rc independently represent groups selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - Rd represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - one of the groups G3 and G4 is a nitrogen atom and the other is a CH group; - M is a hydrogen atom or an pharmaceutically acceptable cation with the proviso that, when at least one of the groups Ra and Rb represent a hydrogen atom and G2 is a group CRd, then Rd represents a groups selected from C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C3-8 cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; and the pharmaceutically acceptable salts and N-oxides thereof.